US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FUNDX FUTURE FUND OPPORTUNITIES ETF

28.35

-0.2000-0.70%

Volume:16.60K

Turnover:470.79K

Market Cap:229.21M

PE:- -

High:28.40

Open:28.31

Low:28.30

Close:28.55

52wk High:31.30

52wk Low:25.44

Shares:8.09M

Float Shares:8.09M

Volume Ratio:1.67

T/O Rate:0.21%

Dividend:0.49

Dividend Rate:1.74%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS

Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live

Guardant Health initiated with a Buy at Rothschild & Co Redburn

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS

Analysts’ Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

Halozyme CEO, CFO to Speak at Wells Fargo Healthcare Conference Fireside Chat

Guardant Health Price Target Maintained with a $195.00/Share by BTIG

Barfresh Food Names CEO Delle Coste Interim CFO as Lisa Roger Retires

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Guardant Health (GH)

Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.

Is Halozyme Therapeutics (HALO) Overvalued After Its New Board Appointment?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/FFOX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FFOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FFOX\",,,,,undefined,":{"symbol":"FFOX","market":"US","secType":"STK","nameCN":"FUNDX FUTURE FUND OPPORTUNITIES ETF","latestPrice":28.35,"timestamp":1789416000000,"preClose":28.55,"halted":0,"volume":16600,"delay":0,"changeRate":-0.007005253940455316,"floatShares":8085000,"shares":8085000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.2,"latestTime":"09-15 08:02:41 EDT","open":28.31,"high":28.4,"low":28.3,"amount":470789,"amplitude":0.003503,"askPrice":45.07,"askSize":100,"bidPrice":11.4,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":28.35,"sharesOutstanding":7155000,"nav":28.53,"aum":230665050,"dividendRate":0.017397,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.35,"preClose":28.35,"latestTime":"16:10 EDT","volume":6,"amount":170.1,"timestamp":1789416603724,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.6665662711081661},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FFOX\",,,,,undefined,":{"symbol":"FFOX","floatShares":8085000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.6665662711081661,"shares":8085000,"dividePrice":0.4932,"high":28.4,"amplitude":0.003503,"preClose":28.55,"low":28.3,"week52Low":25.44,"pbRate":"--","week52High":31.295,"institutionHeld":0,"latestPrice":28.35,"eps":0,"divideRate":0.017397,"volume":16600,"delay":0,"ttmEps":0,"open":28.31,"prevYearClose":27.27,"prevWeekClose":28.55,"prevMonthClose":29.2799,"prevQuarterClose":30.29,"fiveDayClose":29.17,"twentyDayClose":31.215,"sixtyDayClose":28.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FFOX\",params:#limit:5,,,undefined,":[{"date":"2025-12-31","symbol":"FFOX","amount":0.49447507,"announcedDate":"2025-12-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"FUNDX FUTURE FUND OPPORTUNITIES ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-02","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-01-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FFOX\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-31","recordDate":"2025-12-31","paymentDate":"2026-01-02","value":0.49447507,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FFOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FFOX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667569983","title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569983","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569983?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:12","pubTimestamp":1789423938,"startTime":"0","endTime":"0","summary":"Guardant Health CIO Kumud Kalia disposes of 4,000 common shares worth $632,193.20Guardant Health Chief Information Officer Kumud Kalia sold 4,000 common shares on Sept. 11, 2026.The sale price was USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL3DVtS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GNMX","GDOC","GH","LU0320765992.SGD","BK4535","BK4551","BK4585","GNOM","LU0109394709.USD","PTH","EKG","HELX","BK4196","FFOX","LFSC","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667087693","title":"Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667087693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667087693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:07","pubTimestamp":1789416443,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","BK4585","GNOM","LU0109394709.USD","LU0320765992.SGD","FFOX","PTH","GH","LFSC","BK4588","HELX","BK4535","LU0889565916.HKD","GNMX","EKG","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666570911","title":"Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666570911","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666570911?lang=en_us&edition=fundamental","pubTime":"2026-09-12 08:35","pubTimestamp":1789173359,"startTime":"0","endTime":"0","summary":"Halozyme CEO Helen Torley reports disposal of common shares worth USD 6.5 millionHalozyme CEO Helen Torley reported option exercises totaling 60,000 shares from Sept. 9-11, 2026 at USD 18.41.Disposed ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260912:nNDL9QbYMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666368655","title":"UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666368655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666368655?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960920,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EKG","FFOX","GDOC","HELX","BK4196","GNMX","BK4585","LU0320765992.SGD","PTH","BK4535","LU0109394709.USD","GNOM","BK4588","GH","LFSC","BK4551","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373511","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373511?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871865,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), Guardant Health (GH) and Neurocrine (N...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HCSG","NBIX","BK4139","LABU","PJP","LU0029874061.USD","IE00BJT1NW94.SGD","LU1571399168.USD","LU0154245673.USD","LU0289739699.SGD","TBXU","BK4535","GNOM","GDOC","IBBQ","LU0889565916.HKD","LU1057294990.SGD","BK4599","IBB","IE0002141913.USD","IE0009355771.USD","LU1061106388.HKD","BK4588","PBE","BK4534","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","BIB","EKG","PTH","LU2468319806.SGD","GNMX","LFSC","LU0109394709.USD","LU2065170008.USD","BK4137","IE00B2B36J28.USD","AMGN","LU0154245756.USD","LU0823416689.USD","HELX","BBH","GH","XLV","FFOX","LU2242646821.SGD","XBI","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378332","title":"Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378332?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:26","pubTimestamp":1788870360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","GNMX","LU0889565916.HKD","LU0320765992.SGD","GNOM","BK4585","EKG","FFOX","BK4551","GDOC","BK4588","GH","HELX","BK4196","PTH","BK4535","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321994","title":"Guardant Health's Breast Cancer Diagnostic Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321994","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321994?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862114,"startTime":"0","endTime":"0","summary":"Guardant Health's  Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's  Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443895.HKD","AZN","HELX","LU2456880835.USD","LU2462157665.USD","LU0708994859.HKD","AZNH","LU0109394709.USD","LU0289739699.SGD","LU2468319806.SGD","GH","LU0128525929.USD","LU2089984988.USD","LABU","LU2236285917.USD","LU0310800379.SGD","EKG","LU1267930573.SGD","GDOC","LU0320765992.SGD","LU0029864427.USD","FFOX","GNMX","LFSC","LU2237443622.USD","PTH","BK4551","BK4585","LU0432979614.USD","BK4568","LU2237443978.SGD","GNOM","LU0889565916.HKD","LU2417539215.USD","LU1829250122.USD","LU0058720904.USD","BK4007","LU2237443549.SGD","BK4535","BK4196","LU2237443465.HKD","LU2237443382.USD","IE00B3T34201.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665213403","title":"Rothschild & Co Redburn Initiates Guardant Health at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665213403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665213403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861705,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNOM","LU0109394709.USD","BK4196","GH","LFSC","GDOC","LU0320765992.SGD","GNMX","FFOX","PTH","BK4585","LU0889565916.HKD","EKG","BK4551","BK4535","HELX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532615","title":"Guardant Health initiated with a Buy at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532615?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858969,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","FFOX","GNMX","LFSC","HELX","PTH","BK4551","BK4585","GNOM","BK4535","LU0109394709.USD","EKG","BK4196","GH","GDOC","LU0320765992.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","PTH","GNMX","MEDI","FFOX","EKG","BK4535","GNOM","XLVX","BBP","IDNA","GDOC","TECB","NVIB","PINK","HELX","MRNX","LU0889565916.HKD","TBXU","LU0320765992.SGD","BK4196","LABU","GH","LU0109394709.USD","BK4551","FRTY","IEIH","IBB","SYNB","IYH","BK4588","RSPH","BMED","MRNY","LFSC","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354794","title":"Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354794?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:10","pubTimestamp":1788559800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA7GZLSJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4535","BK4196","BK4551","FFOX","EKG","GH","HELX","BK4585","LU0320765992.SGD","GDOC","GNOM","LU0109394709.USD","PTH","BK4588","LFSC","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664846503","title":"Analysts’ Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664846503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664846503?lang=en_us&edition=fundamental","pubTime":"2026-09-03 02:50","pubTimestamp":1788375009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on High Roller Technologies, Inc. (ROLR) and Halozyme (HALO) wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-high-roller-technologies-inc-rolr-halozyme-halo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-na-picks-high-roller-technologies-inc-rolr-halozyme-halo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRLR","ROLR","LU0053671581.USD","BK4141","HALO","FFOX","BK4139","BK4150","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843956","title":"H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664843956?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:40","pubTimestamp":1788367217,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating on Halozyme (HALO) with a $115 price target after Novartis (NVS) signed an option and license agreement wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-views-novartis-alteogen-pact-as-negative-for-halozyme-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-views-novartis-alteogen-pact-as-negative-for-halozyme-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053671581.USD","BK4578","MEDX","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4532","BK4588","LU0320765489.SGD","LU0070302665.USD","IE00B4R5TH58.HKD","BK4585","LU0208291251.USD","IE00BJT1NW94.SGD","IE0002141913.USD","PPH","IE0009355771.USD","IE00BJJMRZ35.SGD","NVS","LU0211331839.USD","BK4007","HALO","BK4139","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811474","title":"Halozyme CEO, CFO to Speak at Wells Fargo Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811474","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811474?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:32","pubTimestamp":1788352367,"startTime":"0","endTime":"0","summary":"Halozyme CEO, CFO to speak at Wells Fargo healthcare conference fireside chatHalozyme will join Wells Fargo’s 21st Annual Healthcare Conference on Sept. 9, 2026, featuring a fireside chat.Management w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL136P6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","FFOX","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818611","title":"Guardant Health Price Target Maintained with a $195.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818611","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818611?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:52","pubTimestamp":1788342720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","PTH","LU0889565916.HKD","FFOX","LU0109394709.USD","GDOC","EKG","BK4551","LU0320765992.SGD","BK4588","BK4585","HELX","BK4535","LFSC","GNOM","BK4196","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664286114","title":"Barfresh Food Names CEO Delle Coste Interim CFO as Lisa Roger Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2664286114","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664286114?lang=en_us&edition=fundamental","pubTime":"2026-09-02 05:34","pubTimestamp":1788298456,"startTime":"0","endTime":"0","summary":"Barfresh Food names CEO Delle Coste interim CFO as Lisa Roger retiresBarfresh CFO Lisa Roger set Sept. 1 as her last day, following a previously disclosed retirement notice.CEO Delle Coste will take o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL2Jk9SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","BK4566","BK4139","IE0002270589.USD","HALO","BK4212","LU0053671581.USD","IE00B19Z3B42.SGD","BRFH","BMRN","IE00B7SZLL34.SGD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664863257","title":"Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Guardant Health (GH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664863257","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664863257?lang=en_us&edition=fundamental","pubTime":"2026-09-02 01:40","pubTimestamp":1788284405,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medtronic (MDT) and Guardant Health (GH) with bullis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-medtronic-mdt-guardant-health-gh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-medtronic-mdt-guardant-health-gh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106261372.USD","LU0072461881.USD","LU0158827781.USD","XBI","IE00BQXX3C00.GBP","LU2271345857.HKD","LU0211331839.USD","MDT","GNOM","GDOC","LU1061106388.HKD","BK4082","EKG","LU1116320737.USD","LU1989771016.USD","LU2028103732.USD","LU2023251221.USD","HELX","LU0432979614.USD","IE00BFXG1179.USD","LU0128526141.USD","LU0109394709.USD","LU2089283258.USD","LU2089284900.SGD","GNMX","LU1291159041.SGD","LU1989764748.USD","LU0976567544.SGD","IE000M9KFDE8.USD","LU0320765489.SGD","PTH","LU0208291251.USD","LU1571399168.USD","IE00B3PB1722.GBP","LFSC","LU1244550221.USD","LU1983299246.USD","XLV","GH","HCSG","IE00BQXX3F31.USD","LU0029874061.USD","BK4535","FFOX","LABU","LU0162691827.USD","LU1506573853.SGD","LU0211326755.USD","LU0265550946.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856780","title":"Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856780","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856780?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:06","pubTimestamp":1788264367,"startTime":"0","endTime":"0","summary":"Guardant Health Shield blood test wins Carelon coverage for colorectal cancer screeningGuardant Health secured Carelon Healthcare Services coverage for its FDA-approved Shield blood test for colorecta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL9hPZ6Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4551","BK4196","GDOC","LU0889565916.HKD","LFSC","LU0320765992.SGD","BK4585","GH","GNOM","FFOX","LU0109394709.USD","EKG","GNMX","BK4535","HELX","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044590","title":"Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044590","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044590?lang=en_us&edition=fundamental","pubTime":"2026-08-30 19:19","pubTimestamp":1788088793,"startTime":"0","endTime":"0","summary":"In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of the judgment and collection of potential royalties paused during the appeal.\nThe court’s royalty order applies mainly to older Guardant tests, while Guardant reports that upgraded versions of key products such as Shield and Reveal, along with validated design changes to Guardant360, fall outside...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GH","BK4551","LU0320765992.SGD","BK4585","BK4535","BK4588","GDOC","FFOX","GNMX","BK4196","HELX","LFSC","GNOM","LU0889565916.HKD","EKG","PTH","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663001175","title":"Is Halozyme Therapeutics (HALO) Overvalued After Its New Board Appointment?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663001175","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663001175?lang=en_us&edition=fundamental","pubTime":"2026-08-29 10:23","pubTimestamp":1787970218,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics (HALO) recently drew attention after electing biotechnology and pharmaceutical executive Dannielle Appelhans to its Board of Directors, prompting investors to reassess the stock’s momentum, valuation, and governance profile.\nThe appointment of Dannielle Appelhans comes as Halozyme Therapeutics trades around US$105.35. The share price return over the past month is up 26.5% and the year to date return is up 49.8%, while the 1 year total shareholder return of 44% and 5 year...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/is-halozyme-therapeutics-halo-overvalued-after-its-new-board","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/is-halozyme-therapeutics-halo-overvalued-after-its-new-board","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","FFOX","ABEQ","BK4139","LU0053671581.USD","HALO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":83,"code":"91000000","status":"200"}]}}